European commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, remsima® sc, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis

Celltrion healthcare today announced that the european commission (ec) has granted marketing authorisation for remsima® (infliximab, ct-p13) subcutane
ADES Ratings Summary
ADES Quant Ranking